Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma

NCT03063632 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

28

Enrollment

NIH

Sponsor class

Conditions

Metastatic Myxoid Liposarcoma
Metastatic Round Cell Liposarcoma
Metastatic Synovial Sarcoma
Recurrent Mycosis Fungoides and Sezary Syndrome
Refractory Mycosis Fungoides and Sezary Syndrome
Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7
Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7
Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7
Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7
Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7
Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7
Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7
Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v7
Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7
Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7
Unresectable Synovial Sarcoma

Interventions

BIOLOGICAL: Interferon Gamma-1b
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Pembrolizumab

Sponsor

National Cancer Institute (NCI)